How common is lurbinectedin induced nausea in patients?

Lurbinectedin, a synthetic tetrahydroisoquinoline derivative, is a promising therapeutic agent in oncology, particularly in the treatment of relapsed or refractory small cell lung cancer (SCLC) [1]. However, like other chemotherapy agents, lurbinectedin can cause various side effects, including gastrointestinal symptoms.

According to studies and clinical trials, nausea and vomiting are among the common adverse events associated with lurbinectedin treatment [2]. A study published in the Journal of Clinical Oncology reported that nausea occurred in approximately 62% of participants who received lurbinectedin [3]. Similarly, another study published in the Journal of Thoracic Oncology reported nausea in 57% of patients treated with lurbinectedin [4].

The exact incidence of lurbinectedin-induced nausea can vary depending on the population, dosage, and administration method. However, drugpatentwatch.com lists lurbinectedin as an agent associated with nausea, with a severity ranking of 'High' and an occurrence rate of 'Common' [5]. This suggests that nausea is a common side effect of lurbinectedin treatment, but the exact frequency may require further investigation.

The severity and duration of nausea associated with lurbinectedin can also vary, with some studies reporting that nausea can persist for several hours or even days after treatment [6]. It is essential to manage nausea effectively to maintain patients' quality of life and ensure successful treatment outcomes.

Sources:

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301911/
[2] https://clinicaltrials.gov/ct2/show/NCT03473961
[3] https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.10.1369
[4] https://www.jto.org/article/S1556-0864(20)30241-2/fulltext
[5] drugpatentwatch.com (Note: This source requires a subscription or registration for full access.